



GeneFrontier

Feb. 21, 2013

GeneFrontier Corporation

Collaboration and License Agreement with the Global Pharmaceutical Company Regarding PUREfrefx RD

GeneFrontier Corporation, a Japan-based biotech company (hereinafter referred to as GFC) announced today the signature with the global pharmaceutical company of collaboration and license agreement regarding its proprietary technology, “PUREfrefx RD.”

GFC has been providing unique products, technologies and services for biological research and biopharmaceutical development. It includes reconstituted cell-free protein synthesis reagent “PUREfrefx®” *1, custom monoclonal antibody generation service based on phage display technology*2 called HuCAL*3 developed by MorphoSys AG, and so on. Now, GFC has succeeded in developing an innovative proprietary technology “PUREfrefx RD”, which significantly improves the efficiency of screening process for development of biopharmaceuticals including antibody drugs.

“PUREfrefx RD” is based on ribosome display technology*4 with “PUREfrefx®.” In “PUREfrefx RD”, appropriate biopharmaceutical candidates can be quickly and easily isolated from the libraries with diversity of more than 100 times larger, in less than half the time, than conventional screening techniques. GFC first introduced “PUREfrefx RD” especially for affinity maturation of antibodies at Protein Engineering Summit in May 2012, and now, has signed a collaboration and license agreement based on “PUREfrefx RD” with the global pharmaceutical company for the first time. Under the agreement, the company can use “PUREfrefx RD” for affinity maturation of biopharmaceuticals including antibody drugs in multi-year at their research institute, and also can collaborate with GFC using “PUREfrefx RD for their development of biologics.”

“We believe the fact that we have signed this agreement in such a short period of time shows the usefulness of “PUREfrefx RD”, and the fact also suggests “PUREfrefx RD” can contribute to biopharmaceutical development in more pharmaceutical companies,” said Dr. Takashi Ebihara, COO of GFC.

GFC will expand collaboration based on PUREfrefx RD with pharmaceutical and diagnostics companies, and establish the position as a unique solution provider in the life science field through

developing new proprietary products, technologies and services contributing to biological research and biopharmaceutical development.

Supplements:

*1 PUREfrex® : Reconstituted cell-free protein synthesis reagent based on PURE system (Protein synthesis Using Recombinant Elements system).

*2 Phage display technology: Screening technique for biopharmaceuticals using a virus infecting Escherichia coli.

*3 HuCAL: It represents Human Combinatorial Antibody Library developed by MorphoSys AG. It's a very innovative highly qualified human antibody library with phage display technology.

*4 Ribosome display technology: Fully in vitro screening technique for biopharmaceuticals without Escherichia coli.